VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

27 Aug 2025 04:02:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

07 Aug 2025 13:05:02 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

17 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

28 May 2025 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

08 May 2025 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

01 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

27 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

18 Feb 2025 05:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

14 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

12 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

07 Nov 2024 13:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

15 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

23 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

06 Sep 2024 05:00:11 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Departure of Chief Financial Officer

30 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

28 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

08 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease

29 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

16 May 2024 13:05:00 By Nasdaq GlobeNewswire